In vitro anti-Acanthamoeba synergistic effect of chlorhexidine and cationic carbosilane dendrimers against both trophozoite and cyst forms.

Acanthamoeba sp. are the causative agents of severe illnesses in humans such as Acanthamoeba keratitis (AK) and granulomatous amoebic encephalitis (GAE). Medical therapy is not yet well established. Treatments of AK last for several months and generate toxicity, resistances appear due to the cysts stage and recurrences can occur. In this study has been demonstrated that the combination of chlorhexidine digluconate (CLX) and carbosilane dendrimers containing ammonium or guanidine moieties has in vitro synergistic effect against Acanthamoeba polyphaga. This synergy provokes an important reduction in the minimal trophozoite amoebicidal concentration (MTAC) of CLX, which means a reduction of their toxic effects on human cells. Moreover, some CLX/dendrimer combinations show important activity against the cyst resistance stage.

[1]  R. Larossa,et al.  Quaternary ammonium functionalized poly(propylene imine) dendrimers as effective antimicrobials: structure-activity studies. , 2000, Biomacromolecules.

[2]  A. Vural,et al.  Effect of combined chlorhexidine gluconate and Neosporin on experimental keratitis with two pathogenic strains of Acanthamoeba , 2011, Parasitology Research.

[3]  W. Mathers.  Use of higher medication concentrations in the treatment of acanthamoeba keratitis. , 2006, Archives of ophthalmology.

[4]  G. Johnson,et al.  Randomised trial of 0.2% chlorhexidine gluconate and 2.5% natamycin for fungal keratitis in Bangladesh , 1998, The British journal of ophthalmology.

[5]  D. Lloyd,et al.  Recent advances in the treatment of Acanthamoeba keratitis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  J. Hebling,et al.  Cytotoxic effects of different concentrations of chlorhexidine. , 2007, American journal of dentistry.

[7]  E. Cohen,et al.  Acanthamoeba Keratitis: A Parasite on the Rise , 2007, Cornea.

[8]  Y. Hirakata,et al.  In Vitro and In Vivo Activities of Novel Fluoroquinolones Alone and in Combination with Clarithromycin against Clinically Isolated Mycobacterium avium Complex Strains in Japan , 2007, Antimicrobial Agents and Chemotherapy.

[9]  J. Walochnik,et al.  Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis , 2014, Clinical & experimental ophthalmology.

[10]  A. D. Russell,et al.  Antiseptics and Disinfectants: Activity, Action, and Resistance , 2001, Clinical Microbiology Reviews.

[11]  Huining Xiao,et al.  Antimicrobial Polymeric Materials with Quaternary Ammonium and Phosphonium Salts , 2015, International journal of molecular sciences.

[12]  N. Khan.  Acanthamoeba: Biology and Pathogenesis , 2009 .

[13]  S. Cooper,et al.  Interactions between dendrimer biocides and bacterial membranes. , 2002, Biomaterials.

[14]  P. Rama,et al.  Double-Biguanide Therapy for Resistant Acanthamoeba Keratitis , 2011, Case Reports in Ophthalmology.

[15]  R. Gómez,et al.  Structure–activity relationship study of cationic carbosilane dendritic systems as antibacterial agents , 2016 .

[16]  Colin Bonduelle,et al.  Dendritic Guanidines as Efficient Analogues of Cell Penetrating Peptides , 2010, Pharmaceuticals.

[17]  R. Gómez,et al.  In vitro evaluation of the effectiveness of new water-stable cationic carbosilane dendrimers against Acanthamoeba castellanii UAH-T17c3 trophozoites , 2012, Parasitology Research.

[18]  D. Seal,et al.  Successful medical therapy of Acanthamoeba keratitis with topical chlorhexidine and propamidine , 1996, Eye.

[19]  G. Cabral,et al.  Acanthamoeba spp. as Agents of Disease in Humans , 2003, Clinical Microbiology Reviews.

[20]  Basilio Valladares,et al.  The potential pathogenicity of chlorhexidine-sensitive Acanthamoeba strains isolated from contact lens cases from asymptomatic individuals in Tenerife, Canary Islands, Spain. , 2008, Journal of medical microbiology.

[21]  Vincent Thomas,et al.  Free-living amoebae and their intracellular pathogenic microorganisms: risks for water quality. , 2010, FEMS microbiology reviews.

[22]  D C Minassian,et al.  Acanthamoeba keratitis in England and Wales: incidence, outcome, and risk factors , 2002, The British journal of ophthalmology.

[23]  A. M. Chudzinski-Tavassi,et al.  Antimicrobial action of biguanides on the viability of Acanthamoeba cysts and assessment of cell toxicity. , 2013, Investigative ophthalmology & visual science.

[24]  K. Miłowska,et al.  Dendrimers--revolutionary drugs for infectious diseases. , 2012, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[25]  A. M. Carmona-Ribeiro,et al.  Cationic Antimicrobial Polymers and Their Assemblies , 2013, International journal of molecular sciences.

[26]  S. Tuft,et al.  Outcome of acanthamoeba keratitis treated with polyhexamethyl biguanide and propamidine. , 1997, Ophthalmology.

[27]  S. Kilvington,et al.  Acanthamoeba keratitis: diagnosis and treatment update 2009. , 2009, American journal of ophthalmology.

[28]  D. Seal,et al.  Acanthamoeba keratitis update—incidence, molecular epidemiology and new drugs for treatment , 2003, Eye.

[29]  N. Khan.  Acanthamoeba: biology and increasing importance in human health. , 2006, FEMS microbiology reviews.

[30]  Benjamin Clarke,et al.  Advances in the Diagnosis and Treatment of Acanthamoeba Keratitis , 2012, Journal of ophthalmology.

[31]  M. Malý,et al.  Carbosilane cationic dendrimers synthesized by thiol–ene click chemistry and their use as antibacterial agents , 2014 .

[32]  J. Copa-Patiño,et al.  Acanthamoeba castellanii: in vitro UAH-T17c3 trophozoite growth study in different culture media , 2012, Parasitology Research.

[33]  A. López-Arencibia,et al.  Therapeutic Potential of a Combination of Two Gene-Specific Small Interfering RNAs against Clinical Strains of Acanthamoeba , 2010, Antimicrobial Agents and Chemotherapy.

[34]  D. Lloyd,et al.  Aspects of the mechanisms of action of biguanides on trophozoites and cysts of Acanthamoeba castellanii , 1997, Journal of applied microbiology.

[35]  G. O’Toole,et al.  Exploiting dendrimer multivalency to combat emerging and re-emerging infectious diseases. , 2012, Molecular pharmaceutics.

[36]  A. Bianco,et al.  Polycationic adamantane-based dendrons of different generations display high cellular uptake without triggering cytotoxicity. , 2014, Journal of the American Chemical Society.

[37]  S. Kilvington,et al.  A clinicopathologic study of in vitro sensitivity testing and Acanthamoeba keratitis. , 1994, Investigative ophthalmology & visual science.

[38]  F. Schuster,et al.  Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals. , 2004, International journal for parasitology.

[39]  Rafael Gomez,et al.  Evaluation of the activity of new cationic carbosilane dendrimers on trophozoites and cysts of Acanthamoeba polyphaga , 2015, Parasitology Research.

[40]  Marta Fernández-García,et al.  Polymeric materials with antimicrobial activity , 2013 .